Search

Displaying results 2631 - 2640 of 10000 in total
  1. Drug

    Chloramphenicol succinate

    go.drugbank.com/drugs/DB07565
    Approved

    [L14174] Chloramphenicol succinate was granted FDA approval on 20 February 1959.[L12711] … [A204065] Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially fatal blood dyscrasias.

    Products: GEMYSETIN SÜKSİNAT 1G I.M./ I.V. ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ, 100 FLAKON, SUMICLORAN ® 1 G INYECTABLE
  2. Drug

    Lactitol

    go.drugbank.com/drugs/DB12942
    Approved

    [A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803] … Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose].

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Bacillus clausii

    go.drugbank.com/drugs/DB16537
    Investigational

    Products: Enterogermina 2 Billions/5 ml oral suspension
  4. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … Bimekizumab was also granted FDA approval on October 18, 2023.[L48551]

  5. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    Blonanserin is an atypical antipsychotic approved in Japan in January, 2008. … As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.

    Categories: Dopamine D2 Receptor Antagonists
  6. Drug

    Favezelimab

    go.drugbank.com/drugs/DB16729
    Investigational

    Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A

  7. Drug

    Isometheptene

    go.drugbank.com/drugs/DB06706
    Approved

    Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.

    Mixtures: DIPIRONA 300 MG + ISOMETEPTENO MUCATO 30 MG + CAFEINA 30 MG, DIPIRONA 300 MG + ISOMETEPTENO 50 MG + CAFEINA 30 MG GOTAS
  8. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    [A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may

  9. Drug

    Aloe vera leaf

    go.drugbank.com/drugs/DB13906
    ApprovedInvestigational

    Aloe describes a genus including over 500 species of flowering succulent plants that grow in the Southern peninsula and various islands. … While aloe vera has a long history of commercial uses, it is still widely used in cosmetic, food and pharmaceutical products.

    Mixtures: Re-action E, Nail Care PenSynonyms: Lu hui ye, Lu hui (aloe vera)
  10. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.

    Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-